Key points are not available for this paper at this time.
Overexpression of human epidermal growth factor receptor type 2 (HER2) in breast cancer is associated with decreased overall survival. Trastuzumab, a humanized monoclonal antibody that targets HER2, is approved by the Food and Drug Administration for patients with invasive breast cancers that overexpress HER2. This review considers the mechanism of action and the use of this agent.
Building similarity graph...
Analyzing shared references across papers
Loading...
Clifford A. Hudis
New England Journal of Medicine
Memorial Sloan Kettering Cancer Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Clifford A. Hudis (Wed,) studied this question.
www.synapsesocial.com/papers/6a03b3b5f6c0e004a6de0a46 — DOI: https://doi.org/10.1056/nejmra043186
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: